doi:10.48130/targetome-0026-0050

[1]

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, et al. 2024. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 74:229−263

doi: 10.3322/caac.21834

[2]

Fink H, Langselius O, Vignat J, Rumgay H, Rehm J, et al. 2026. Global and regional cancer burden attributable to modifiable risk factors to inform prevention. Nature Medicine 32:1306−1315

doi: 10.1038/s41591-026-04219-7

[3]

Sung H, Filho AM, Laversanne M, Ferlay J, Siegel RL, et al. 2026. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA: A Cancer Journal for Clinicians 76:e70090

doi: 10.3322/caac.70090

[4]

World Health Organization. 2026. Global status report on cancer 2026: the future we choose together. Geneva: World Health Organization

[5]

Rosenberg SA, Restifo NP. 2015. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348:62−68

doi: 10.1126/science.aaa4967

[6]

June CH, Sadelain M. 2018. Chimeric antigen receptor therapy. The New England Journal of Medicine 379:64−73

doi: 10.1056/NEJMra1706169

[7]

Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, et al. 2022. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. Journal for Immunotherapy of Cancer 10:e005755

doi: 10.1136/jitc-2022-005755

[8]

Hu L, Fan C, Bross P, Das A, Cho ES, et al. 2025. FDA approval summary: lifileucel for unresectable or metastatic melanoma previously treated with an anti-PD-1-based immunotherapy. Clinical Cancer Research 31:4004−4009

doi: 10.1158/1078-0432.CCR-25-0880

[9]

Eshhar Z, Waks T, Gross G, Schindler DG. 1993. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proceedings of the National Academy of Sciences of the United States of America 90:720−724

doi: 10.1073/pnas.90.2.720

[10]

Chandran SS, Klebanoff CA. 2019. T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance. Immunological Reviews 290:127−147

doi: 10.1111/imr.12772

[11]

Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, et al. 2021. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. The New England Journal of Medicine 384:705−716

doi: 10.1056/NEJMoa2024850

[12]

Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, et al. 2021. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. The Lancet 398:314−324

doi: 10.1016/S0140-6736(21)00933-8

[13]

Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, et al. 2024. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. The New England Journal of Medicine 391:2219−2230

doi: 10.1056/NEJMoa2406526

[14]

Labanieh L, MacKall CL. 2023. CAR immune cells: design principles, resistance and the next generation. Nature 614:635−648

doi: 10.1038/s41586-023-05707-3

[15]

Rafiq S, Hackett CS, Brentjens RJ. 2020. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature Reviews Clinical Oncology 17:147−167

doi: 10.1038/s41571-019-0297-y

[16]

Sun F, Cheng Y, Wanchai V, Guo W, Mery D, et al. 2024. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nature Communications 15:615

doi: 10.1038/s41467-024-44873-4

[17]

Sun F, Cheng Y, Chen JR, Wanchai V, Mery DE, et al. 2024. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. The Journal of Clinical Investigation 134:e171396

doi: 10.1172/JCI171396

[18]

Escobar G, Berger TR, Maus MV. 2025. CAR-T cells in solid tumors: challenges and breakthroughs. Cell Reports Medicine 6:102353

doi: 10.1016/j.xcrm.2025.102353

[19]

Du B, Qin J, Lin B, Zhang J, Li D, et al. 2025. CAR-T therapy in solid tumors. Cancer Cell 43:665−679

doi: 10.1016/j.ccell.2025.03.019

[20]

Barnett KK, Johnson AR, Das A, Lee CJ, Wang C, et al. 2025. FDA approval summary: afamitresgene autoleucel for adults with HLA-restricted, MAGE-A4-positive unresectable or metastatic synovial sarcoma after prior chemotherapy. Clinical Cancer Research 31:3112−3117

doi: 10.1158/1078-0432.CCR-25-0595

[21]

D'Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, et al. 2024. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. The Lancet 403:1460−1471

doi: 10.1016/S0140-6736(24)00319-2

[22]

Qi C, Liu C, Peng Z, Zhang Y, Wei J, et al. 2025. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. The Lancet 405:2049−2060

doi: 10.1016/S0140-6736(25)00860-8

[23]

Wermke M, Araujo DM, Chatterjee M, Tsimberidou AM, Holderried TAW, et al. 2025. Autologous T cell therapy for PRAME⁺ advanced solid tumors in HLA-A*02⁺ patients: a phase 1 trial. Nature Medicine 31:2365−2374

doi: 10.1038/s41591-025-03650-6

[24]

2026. First CAR T for solid tumors. Nature Biotechnology 44:1068

[25]

Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, et al. 2015. Tissue-based map of the human proteome. Science 347:1260419

doi: 10.1126/science.1260419

[26]

Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, et al. 2020. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discovery 10:702−723

doi: 10.1158/2159-8290.CD-19-0945

[27]

Watanabe K, Terakura S, Martens AC, van Meerten T, Uchiyama S, et al. 2015. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8⁺ T cells. The Journal of Immunology 194:911−920

doi: 10.4049/jimmunol.1402346

[28]

Huang J, Brameshuber M, Zeng X, Xie J, Li QJ, et al. 2013. A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4⁺ T cells. Immunity 39:846−857

doi: 10.1016/j.immuni.2013.08.036

[29]

Consortium GT. 2020. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369:1318−1330

doi: 10.1126/science.aaz1776

[30]

Marcu A, Bichmann L, Kuchenbecker L, Kowalewski DJ, Freudenmann LK, et al. 2021. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. Journal for ImmunoTherapy of Cancer 9:e002071

doi: 10.1136/jitc-2020-002071

[31]

Purcell AW, Ramarathinam SH, Ternette N. 2019. Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics. Nature Protocols 14:1687−1707

doi: 10.1038/s41596-019-0133-y

[32]

Yewdell JW. 2022. MHC class I immunopeptidome: past, present, and future. Molecular & Cellular Proteomics 21:100230

doi: 10.1016/j.mcpro.2022.100230

[33]

Hernandez-Lopez RA, Yu W, Cabral KA, Creasey OA, Lopez Pazmino MDP, et al. 2021. T cell circuits that sense antigen density with an ultrasensitive threshold. Science 371:1166−1171

doi: 10.1126/science.abc1855

[34]

Olivier T, Haslam A, Tuia J, Prasad V. 2023. Eligibility for human leukocyte antigen-based therapeutics by race and ethnicity. JAMA Network Open 6:e2338612

doi: 10.1001/jamanetworkopen.2023.38612

[35]

Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, et al. 2017. Defining a cancer dependency map. Cell 170:564−576.e16

doi: 10.1016/j.cell.2017.06.010

[36]

Łuksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, et al. 2017. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature 551:517−520

doi: 10.1038/nature24473

[37]

Łuksza M, Sethna ZM, Rojas LA, Lihm J, Bravi B, et al. 2022. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature 606:389−395

doi: 10.1038/s41586-022-04735-9

[38]

Leidner R, Sanjuan Silva N, Huang H, Sprott D, Zheng C, et al. 2022. Neoantigen T-cell receptor gene therapy in pancreatic cancer. The New England Journal of Medicine 386:2112−2119

doi: 10.1056/NEJMoa2119662

[39]

Ely ZA, Kulstad ZJ, Gunaydin G, Addepalli S, Verzani EK, et al. 2025. Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition. Science 388:eadk3487

doi: 10.1126/science.adk3487

[40]

Goncalves G, Dolcetti R, Ooi JD, Faridi P. 2025. Cryptic but critical: non-canonical antigens in cancer immunotherapy. Trends in Immunology 46:499−501

doi: 10.1016/j.it.2025.06.002

[41]

Apavaloaei A, Zhao Q, Hesnard L, Cahuzac M, Durette C, et al. 2025. Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer. Nature Cancer 6:1419−1437

doi: 10.1038/s43018-025-00979-2

[42]

Bausch-Fluck D, Goldmann U, Müller S, van Oostrum M, Müller M, et al. 2018. The in silico human surfaceome. Proceedings of the National Academy of Sciences of the United States of America 115:E10988−E10997

doi: 10.1073/pnas.1808790115

[43]

Sterner RC, Sterner RM. 2021. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer Journal 11:69

doi: 10.1038/s41408-021-00459-7

[44]

van der Stegen SJC, Hamieh M, Sadelain M. 2015. The pharmacology of second-generation chimeric antigen receptors. Nature Reviews Drug Discovery 14:499−509

doi: 10.1038/nrd4597

[45]

Chmielewski M, Abken H. 2015. TRUCKs: the fourth generation of CARs. Expert Opinion on Biological Therapy 15:1145−1154

doi: 10.1517/14712598.2015.1046430

[46]

Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, et al. 2018. A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects. Nature Medicine 24:352−359

doi: 10.1038/nm.4478

[47]

Dong D, Zheng L, Lin J, Zhang B, Zhu Y, et al. 2019. Structural basis of assembly of the human T cell receptor–CD3 complex. Nature 573:546−552

doi: 10.1038/s41586-019-1537-0

[48]

Gaud G, Lesourne R, Love PE. 2018. Regulatory mechanisms in T cell receptor signalling. Nature Reviews Immunology 18:485−497

doi: 10.1038/s41577-018-0020-8

[49]

Shah K, Al-Haidari A, Sun J, Kazi JU. 2021. T cell receptor (TCR) signaling in health and disease. Signal Transduction and Targeted Therapy 6:412

doi: 10.1038/s41392-021-00823-w

[50]

Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. 2014. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nature Reviews Cancer 14:135−146

doi: 10.1038/nrc3670

[51]

He W, Cui K, Farooq MA, Huang N, Zhu S, et al. 2025. TCR-T cell therapy for solid tumors: challenges and emerging solutions. Frontiers in Pharmacology 16:1493346

doi: 10.3389/fphar.2025.1493346

[52]

Bassani-Sternberg M, Pletscher-Frankild S, Jensen LJ, Mann M. 2015. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Molecular & Cellular Proteomics 14:658−673

doi: 10.1074/mcp.M114.042812

[53]

Saotome K, Dudgeon D, Colotti K, Moore MJ, Jones J, et al. 2023. Structural analysis of cancer-relevant TCR-CD3 and peptide-MHC complexes by cryoEM. Nature Communications 14:2401

doi: 10.1038/s41467-023-37532-7

[54]

Stone JD, Chervin AS, Kranz DM. 2009. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology 126:165−176

doi: 10.1111/j.1365-2567.2008.03015.x

[55]

Valitutti S, Muller S, Cella M, Padovan E, Lanzavecchia A. 1995. Serial triggering of many T-cell receptors by a few peptide–MHC complexes. Nature 375:148−151

doi: 10.1038/375148a0

[56]

Zhao X, Kolawole EM, Chan W, Feng Y, Yang X, et al. 2022. Tuning T cell receptor sensitivity through catch bond engineering. Science 376:eabl5282

doi: 10.1126/science.abl5282

[57]

Ramakrishna S, Highfill SL, Walsh Z, Nguyen SM, Lei H, et al. 2019. Modulation of target antigen density improves CAR T-cell functionality and persistence. Clinical Cancer Research 25:5329−5341

doi: 10.1158/1078-0432.CCR-18-3784

[58]

Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, et al. 2018. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nature Medicine 24:1504−1506

doi: 10.1038/s41591-018-0146-z

[59]

Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, et al. 2018. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nature Medicine 24:20−28

doi: 10.1038/nm.4441

[60]

Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, et al. 2021. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nature Communications 12:868

doi: 10.1038/s41467-021-21177-5

[61]

Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, et al. 2013. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122:863−871

doi: 10.1182/blood-2013-03-490565

[62]

Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, et al. 2013. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Science Translational Medicine 5:197ra103

doi: 10.1126/scitranslmed.3006034

[63]

Rohaan MW, Borch TH, van den Berg JH, Met Ö, Kessels R, et al. 2022. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. The New England Journal of Medicine 387:2113−2125

doi: 10.1056/NEJMoa2210233

[64]

Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, et al. 2010. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy 18:843−851

doi: 10.1038/mt.2010.24

[65]

Simpson AJG, Caballero OL, Jungbluth A, Chen YT, Old LJ. 2005. Cancer/testis antigens, gametogenesis and cancer. Nature Reviews Cancer 5:615−625

doi: 10.1038/nrc1669

[66]

Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, et al. 2011. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Journal of Clinical Oncology 29:917−924

doi: 10.1200/JCO.2010.32.2537

[67]

Luke JJ, Warner AB, Chmielowski B, Diab A, Gebhardt C, et al. 2025. SUPRAME: a phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator's choice in patients with previously treated advanced cutaneous melanoma. Journal of Clinical Oncology 43:TPS2673

doi: 10.1200/JCO.2025.43.16_suppl.TPS2673

[68]

Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, et al. 2004. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Research 64:9167−9171

doi: 10.1158/0008-5472.CAN-04-1442

[69]

Schumacher TN, Schreiber RD. 2015. Neoantigens in cancer immunotherapy. Science 348:69−74

doi: 10.1126/science.aaa4971

[70]

Parkhurst MR, Robbins PF, Tran E, Prickett TD, Gartner JJ, et al. 2019. Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discovery 9:1022−1035

doi: 10.1158/2159-8290.CD-18-1494

[71]

Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, et al. 2016. T-cell transfer therapy targeting mutant KRAS in cancer. The New England Journal of Medicine 375:2255−2262

doi: 10.1056/NEJMoa1609279

[72]

Kim SP, Vale NR, Zacharakis N, Krishna S, Yu Z, et al. 2022. Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. Cancer Immunology Research 10:932−946

doi: 10.1158/2326-6066.CIR-22-0040

[73]

Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, et al. 2021. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nature Medicine 27:419−425

doi: 10.1038/s41591-020-01225-1

[74]

Doran SL, Stevanovic S, Adhikary S, Gartner JJ, Jia L, et al. 2019. T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I/II study. Journal of Clinical Oncology 37:2759−2768

doi: 10.1200/JCO.18.02424

[75]

Straathof KCM, Bollard CM, Popat U, Huls MH, Lopez T, et al. 2005. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes. Blood 105:1898−1904

doi: 10.1182/blood-2004-07-2975

[76]

Wu XA, Quan D, Li W, Wisskirchen K, Wu W, et al. 2026. Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial. Gut 75:147−160

doi: 10.1136/gutjnl-2025-335456

[77]

Hansen UK, Church CD, Carnaz Simões AM, Frej MS, Bentzen AK, et al. 2024. T antigen-specific CD8⁺ T cells associate with PD-1 blockade response in virus-positive Merkel cell carcinoma. The Journal of Clinical Investigation 134:e177082

doi: 10.1172/JCI177082

[78]

Cobbold M, De La Peña H, Norris A, Polefrone JM, Qian J, et al. 2013. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Science Translational Medicine 5:203ra125

doi: 10.1126/scitranslmed.3006061

[79]

Zarling AL, Polefrone JM, Evans AM, Mikesh LM, Shabanowitz J, et al. 2006. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America 103:14889−14894

doi: 10.1073/pnas.0604045103

[80]

Posey AD Jr, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, et al. 2016. Engineered CAR T cells targeting the cancer-associated tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity 44:1444−1454

doi: 10.1016/j.immuni.2016.05.014

[81]

Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, et al. 2018. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M⁺ diffuse midline gliomas. Nature Medicine 24:572−579

doi: 10.1038/s41591-018-0006-x

[82]

Burr ML, Sparbier CE, Chan KL, Chan YC, Kersbergen A, et al. 2019. An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell 36:385−401.e8

doi: 10.1016/j.ccell.2019.08.008

[83]

Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, et al. 2023. γ-secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. The Lancet Oncology 24:811−822

doi: 10.1016/S1470-2045(23)00246-2

[84]

Hundal J, Kiwala S, McMichael J, Miller CA, Xia H, et al. 2020. pVACtools: a computational toolkit to identify and visualize cancer neoantigens. Cancer Immunology Research 8:409−420

doi: 10.1158/2326-6066.CIR-19-0401

[85]

Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. 2020. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Research 48:W449−W454

doi: 10.1093/nar/gkaa379

[86]

O'Donnell TJ, Rubinsteyn A, Laserson U. 2020. MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing. Cell Systems 11:42−48.e7

doi: 10.1016/j.cels.2020.06.010

[87]

Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, et al. 2014. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515:572−576

doi: 10.1038/nature14001

[88]

Chong C, Muller M, Pak H, Harnett D, Huber F, et al. 2020. Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nature Communications 11:1293

doi: 10.1038/s41467-020-14968-9

[89]

Ingolia NT, Ghaemmaghami S, Newman JR, Weissman JS. 2009. Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Science 324:218−223

doi: 10.1126/science.1168978

[90]

Ouspenskaia T, Law T, Clauser KR, Klaeger S, Sarkizova S, et al. 2022. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nature Biotechnology 40:209−217

doi: 10.1038/s41587-021-01021-3

[91]

Yi X, Liao Y, Wen B, Li K, Dou Y, et al. 2021. caAtlas: an immunopeptidome atlas of human cancer. iScience 24:103107

doi: 10.1016/j.isci.2021.103107

[92]

Lu T, Zhang Z, Zhu J, Wang Y, Jiang P, et al. 2021. Deep learning-based prediction of the T cell receptor–antigen binding specificity. Nature Machine Intelligence 3:864−875

doi: 10.1038/s42256-021-00383-2

[93]

Albert BA, Yang Y, Shao XM, Singh D, Smith KN, et al. 2023. Deep neural networks predict class I major histocompatibility complex epitope presentation and transfer learn neoepitope immunogenicity. Nature Machine Intelligence 5:861−872

doi: 10.1038/s42256-023-00694-6

[94]

Klebanoff CA, Chandran SS, Baker BM, Quezada SA, Ribas A. 2023. T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Nature Reviews Drug Discovery 22:996−1017

doi: 10.1038/s41573-023-00809-z

[95]

Hsiue EH, Wright KM, Douglass J, Hwang MS, Mog BJ, et al. 2021. Targeting a neoantigen derived from a common TP53 mutation. Science 371:eabc8697

doi: 10.1126/science.abc8697

[96]

Douglass J, Hsiue EH, Mog BJ, Hwang MS, DiNapoli SR, et al. 2021. Bispecific antibodies targeting mutant RAS neoantigens. Science Immunology 6:eabd5515

doi: 10.1126/sciimmunol.abd5515

[97]

Dao T, Yan S, Veomett N, Pankov D, Zhou L, et al. 2013. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science Translational Medicine 5:176ra33

doi: 10.1126/scitranslmed.3005661

[98]

Baeuerle PA, Ding J, Patel E, Thorausch N, Horton H, et al. 2019. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nature Communications 10:2087

doi: 10.1038/s41467-019-10097-0

[99]

Liu Y, Liu G, Wang J, Zheng ZY, Jia L, et al. 2021. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Science Translational Medicine 13:eabb5191

doi: 10.1126/scitranslmed.abb5191

[100]

Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, et al. 2022. HLA-independent T cell receptors for targeting tumors with low antigen density. Nature Medicine 28:345−352

doi: 10.1038/s41591-021-01621-1

[101]

Hassan R, Butler M, O'Cearbhaill RE, Oh DY, Johnson M, et al. 2023. Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results. Nature Medicine 29:2099−2109

doi: 10.1038/s41591-023-02452-y

[102]

Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, et al. 2012. Monoclonal TCR-redirected tumor cell killing. Nature Medicine 18:980−987

doi: 10.1038/nm.2764

[103]

Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, et al. 2021. Overall survival benefit with tebentafusp in metastatic uveal melanoma. The New England Journal of Medicine 385:1196−1206

doi: 10.1056/NEJMoa2103485

[104]

Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, et al. 2023. Three-year overall survival with tebentafusp in metastatic uveal melanoma. The New England Journal of Medicine 389:2256−2266

doi: 10.1056/NEJMoa2304753

[105]

Majzner RG, Mackall CL. 2018. Tumor antigen escape from CAR T-cell therapy. Cancer Discovery 8:1219−1226

doi: 10.1158/2159-8290.CD-18-0442

[106]

Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, et al. 2015. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discovery 5:1282−1295

doi: 10.1158/2159-8290.CD-15-1020

[107]

Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, et al. 2016. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127:2406−2410

doi: 10.1182/blood-2015-08-665547

[108]

Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, et al. 2019. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568:112−116

doi: 10.1038/s41586-019-1054-1

[109]

O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, et al. 2017. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Science Translational Medicine 9:eaaa0984

doi: 10.1126/scitranslmed.aaa0984

[110]

McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, et al. 2017. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171:1259−1271.e11

doi: 10.1016/j.cell.2017.10.001

[111]

Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, et al. 2016. Mutations associated with acquired resistance to PD-1 blockade in melanoma. The New England Journal of Medicine 375:819−829

doi: 10.1056/NEJMoa1604958

[112]

Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DN, et al. 2011. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Molecular Therapy 19:620−626

doi: 10.1038/mt.2010.272

[113]

Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, et al. 2021. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nature Medicine 27:2099−2103

doi: 10.1038/s41591-021-01564-7

[114]

Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, et al. 2013. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. Journal of Immunotherapy 36:133−151

doi: 10.1097/CJI.0b013e3182829903

[115]

Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, et al. 2010. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nature Medicine 16:565−570

doi: 10.1038/nm.2128

[116]

Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, et al. 2015. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nature Medicine 21:581−590

doi: 10.1038/nm.3838

[117]

Liu X, Jiang S, Fang C, Yang S, Olalere D, et al. 2015. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Research 75:3596−3607

doi: 10.1158/0008-5472.CAN-15-0159

[118]

Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, et al. 2015. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Research 75:3505−3518

doi: 10.1158/0008-5472.CAN-15-0139

[119]

Wermke M, Alsdorf W, Araujo DM, Busse A, Chatterjee M, et al. 2025. Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma. Journal of Clinical Oncology 43:2508−2508

doi: 10.1200/JCO.2025.43.16_suppl.2508

[120]

Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. 2013. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nature Biotechnology 31:71−75

doi: 10.1038/nbt.2459

[121]

Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, et al. 2016. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164:770−779

doi: 10.1016/j.cell.2016.01.011

[122]

Fedorov VD, Themeli M, Sadelain M. 2013. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Science Translational Medicine 5:215ra172

doi: 10.1126/scitranslmed.3006597

[123]

Hwang MS, Mog BJ, Douglass J, Pearlman AH, Hsiue EH, et al. 2021. Targeting loss of heterozygosity for cancer-specific immunotherapy. Proceedings of the National Academy of Sciences of the United States of America 118:e2022410118

doi: 10.1073/pnas.2022410118

[124]

Cho JH, Collins JJ, Wong WW. 2018. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173:1426−1438.e11

doi: 10.1016/j.cell.2018.03.038

[125]

Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, et al. 2016. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. The Journal of Clinical Investigation 126:3036−3052

doi: 10.1172/JCI83416

[126]

Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. 2006. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Research 66:8878−8886

doi: 10.1158/0008-5472.CAN-06-1450

[127]

Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, et al. 2007. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109:2331−2338

doi: 10.1182/blood-2006-05-023069

[128]

Schober K, Müller TR, Gökmen F, Grassmann S, Effenberger M, et al. 2019. Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function. Nature Biomedical Engineering 3:974−984

doi: 10.1038/s41551-019-0409-0

[129]

Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJC, Hamieh M, et al. 2017. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543:113−117

doi: 10.1038/nature21405

[130]

Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, et al. 2012. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119:4133−4141

doi: 10.1182/blood-2011-12-400044

[131]

Chmielewski M, Abken H. 2017. CAR T cells releasing IL-18 convert to T-Bet^high FoxO1^low effectors that exhibit augmented activity against advanced solid tumors. Cell Reports 21:3205−3219

doi: 10.1016/j.celrep.2017.11.063

[132]

Rai S, Wang S, Sun B, Kearl T, Hematti P, et al. 2026. Abstract 1520: improving BCMA-targeted CAR-T cell therapy of myeloma using TGF-β resistance and inducible production of IL-18. Cancer Research 86:1520−1520

doi: 10.1158/1538-7445.Am2026-1520

[133]

Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, et al. 2022. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature Medicine 28:724−734

doi: 10.1038/s41591-022-01726-1

[134]

Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, et al. 2019. C-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576:293−300

doi: 10.1038/s41586-019-1805-z

[135]

Doan AE, Mueller KP, Chen AY, Rouin GT, Chen Y, et al. 2024. FOXO1 is a master regulator of memory programming in CAR T cells. Nature 629:211−218

doi: 10.1038/s41586-024-07300-8

[136]

Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, et al. 2020. CRISPR-engineered T cells in patients with refractory cancer. Science 367:eaba7365

doi: 10.1126/science.aba7365

[137]

Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, et al. 2023. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. The New England Journal of Medicine 389:899−910

doi: 10.1056/NEJMoa2300709

[138]

Chiesa R, Georgiadis C, Rashed H, Preece R, Hardefeldt P, et al. 2025. Universal base-edited CAR7 T cells for T-cell acute lymphoblastic leukemia. The New England Journal of Medicine 394:152−165

doi: 10.1056/NEJMoa2505478

[139]

Rurik JG, Tombácz I, Yadegari A, Méndez Fernández PO, Shewale SV, et al. 2022. CAR T cells produced in vivo to treat cardiac injury. Science 375:91−96

doi: 10.1126/science.abm0594

[140]

Hunter TL, Bao Y, Zhang Y, Matsuda D, Riener R, et al. 2025. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388:1311−1317

doi: 10.1126/science.ads8473

[141]

Rodriguez-Garcia A, Lynn RC, Poussin M, Eiva MA, Shaw LC, et al. 2021. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nature Communications 12:877

doi: 10.1038/s41467-021-20893-2

[142]

Mateus-Tique J, Lakshmi A, Singh B, Iyer R, Sánchez-Paulete AR, et al. 2026. Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth. Cancer Cell 44:534−550.e11

doi: 10.1016/j.ccell.2025.12.021

[143]

Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, et al. 2020. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nature Biotechnology 38:947−953

doi: 10.1038/s41587-020-0462-y

[144]

Reiss KA, Angelos MG, Dees EC, Yuan Y, Ueno NT, et al. 2025. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nature Medicine 31:1171−1182

doi: 10.1038/s41591-025-03495-z

[145]

Jumper J, Evans R, Pritzel A, Green T, Figurnov M, et al. 2021. Highly accurate protein structure prediction with AlphaFold. Nature 596:583−589

doi: 10.1038/s41586-021-03819-2

[146]

Abramson J, Adler J, Dunger J, Evans R, Green T, et al. 2024. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630:493−500

doi: 10.1038/s41586-024-07487-w

[147]

Lin Z, Akin H, Rao R, Hie B, Zhu Z, et al. 2023. Evolutionary-scale prediction of atomic-level protein structure with a language model. Science 379:1123−1130

doi: 10.1126/science.ade2574

[148]

Watson JL, Juergens D, Bennett NR, Trippe BL, Yim J, et al. 2023. De novo design of protein structure and function with RFdiffusion. Nature 620:1089−1100

doi: 10.1038/s41586-023-06415-8

[149]

Dauparas J, Anishchenko I, Bennett N, Bai H, Ragotte RJ, et al. 2022. Robust deep learning-based protein sequence design using ProteinMPNN. Science 378:49−56

doi: 10.1126/science.add2187

[150]

Bradley P. 2023. Structure-based prediction of T cell receptor: peptide-MHC interactions. eLife 12:e82813

doi: 10.7554/eLife.82813

[151]

Householder KD, Xiang X, Jude KM, Deng A, Obenaus M, et al. 2025. De novo design and structure of a peptide-centric TCR mimic binding module. Science 389:375−379

doi: 10.1126/science.adv3813

[152]

Johansen KH, Wolff DS, Scapolo B, Fernández-Quintero ML, Risager Christensen C, et al. 2025. De novo-designed pMHC binders facilitate T cell–mediated cytotoxicity toward cancer cells. Science 389:380−385

doi: 10.1126/science.adv0422

[153]

Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA. 2015. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 350:aab4077

doi: 10.1126/science.aab4077

[154]

Li HS, Israni DV, Gagnon KA, Gan KA, Raymond MH, et al. 2022. Multidimensional control of therapeutic human cell function with synthetic gene circuits. Science 378:1227−1234

doi: 10.1126/science.ade0156

[155]

Teixeira AP, Fussenegger M. 2024. Synthetic gene circuits for regulation of next-generation cell-based therapeutics. Advanced Science 11:2309088

doi: 10.1002/advs.202309088

[156]

Theodoris CV, Xiao L, Chopra A, Chaffin MD, Al Sayed ZR, et al. 2023. Transfer learning enables predictions in network biology. Nature 618:616−624

doi: 10.1038/s41586-023-06139-9

[157]

Tsahouridis O, Xu M, Song F, Savoldo B, Dotti G. 2025. The landscape of CAR-engineered innate immune cells for cancer immunotherapy. Nature Cancer 6:1145−1156

doi: 10.1038/s43018-025-01015-z

[158]

Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, et al. 2020. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. The New England Journal of Medicine 382:545−553

doi: 10.1056/NEJMoa1910607

[159]

Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, et al. 2023. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nature Medicine 29:1379−1388

doi: 10.1038/s41591-023-02363-y

[160]

Liu X, Xu Y, Xiong W, Yin B, Huang Y, et al. 2022. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy. Journal for Immunotherapy of Cancer 10:e004035

doi: 10.1136/jitc-2021-004035

[161]

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, et al. 2017. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. The New England Journal of Medicine 376:836−847

doi: 10.1056/NEJMoa1609783

[162]

Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, et al. 2022. Teclistamab in relapsed or refractory multiple myeloma. New England Journal of Medicine 387:495−505

doi: 10.1056/NEJMoa2203478

[163]

Chari A, Minnema Mc, Berdeja JG, Oriol A, van de Donk NWCJ, et al. 2022. Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma. The New England Journal of Medicine 387:2232−2244

doi: 10.1056/NEJMoa2204591

[164]

Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, et al. 2020. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nature Medicine 26:1569−1575

doi: 10.1038/s41591-020-1081-3

[165]

Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, et al. 2020. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. Journal of Clinical Oncology 38:3794−3804

doi: 10.1200/JCO.20.01342

[166]

Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, et al. 2022. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603:934−941

doi: 10.1038/s41586-022-04489-4

[167]

Monje M, Mahdi J, Majzner R, Yeom KW, Schultz LM, et al. 2025. Intravenous and intracranial GD2-CAR T cells for H3K27M⁺ diffuse midline gliomas. Nature 637:708−715

doi: 10.1038/s41586-024-08171-9

[168]

Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, et al. 2019. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clinical Cancer Research 25:2560−2574

doi: 10.1158/1078-0432.CCR-18-0432

[169]

Vitanza NA, Ronsley R, Choe M, Seidel K, Huang W, et al. 2025. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nature Medicine 31:861−868

doi: 10.1038/s41591-024-03451-3

[170]

Zhu H, Fang X, Tuhin IJ, Tan J, Ye J, et al. 2022. CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer. Journal of Cancer Research and Clinical Oncology 148:2261−2274

doi: 10.1007/s00432-022-04017-x

[171]

Feng Z, He X, Zhang X, Wu Y, Xing B, et al. 2022. Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues. Nature Cancer 3:581−594

doi: 10.1038/s43018-022-00344-7

[172]

Pal SK, Tran B, Haanen JBAG, Hurwitz ME, Sacher A, et al. 2024. CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma. Cancer Discovery 14:1176−1189

doi: 10.1158/2159-8290.CD-24-0102

[173]

Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, et al. 2019. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma. Cancer Immunology Research 7:100−112

doi: 10.1158/2326-6066.CIR-18-0307

[174]

Wang Y, Chen M, Wu Z, Tong C, Dai H, et al. 2018. CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial. OncoImmunology 7:e1440169

doi: 10.1080/2162402X.2018.1440169

[175]

Heslop HE, Sharma S, Rooney CM. 2021. Adoptive T-cell therapy for Epstein-Barr virus-related lymphomas. Journal of Clinical Oncology 39:514−524

doi: 10.1200/JCO.20.01709

[176]

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, et al. 2018. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. The New England Journal of Medicine 378:439−448

doi: 10.1056/NEJMoa1709866

[177]

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, et al. 2017. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. The New England Journal of Medicine 377:2531−2544

doi: 10.1056/NEJMoa1707447

[178]

Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, et al. 2020. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. The New England Journal of Medicine 382:1331−1342

doi: 10.1056/NEJMoa1914347

[179]

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, et al. 2020. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. The Lancet 396:839−852

doi: 10.1016/S0140-6736(20)31366-0

[180]

Britton K, Mahat U, Richardson NC, Tegenge M, Gao Q, et al. 2025. FDA approval summary: lisocabtagene maraleucel for relapsed or refractory follicular lymphoma. Clinical Cancer Research 31:3830−3833

doi: 10.1158/1078-0432.CCR-25-1035

[181]

Schmitz F, Schumacher M, Heine A, Busch A, Heine M, et al. 2024. Sequential dosing of next-generation IMA203CD8 TCR-T-cell therapy targeting PRAME in combination with BRAF-/MEK-inhibition in a melanoma patient with progressive disease - a case report. Blood 144:7194−7194

doi: 10.1182/blood-2024-194461